Title:
MONOCLONAL ANTIBODY FOR SPIKE PROTEIN OF MIDDLE EAST RESPIRATORY SYNDROME CORONAVIRUS, AND USE THEREOF
Document Type and Number:
WIPO Patent Application WO/2019/039891
Kind Code:
A1
Abstract:
The present invention relates to a monoclonal antibody for a spike protein of the Middle East respiratory syndrome coronavirus (MERS-CoV), and a use thereof. Particularly, monoclonal antibodies 77-A5, 77-A6, 90-A3, 90-A9, 90-B2, 90-B7, 90-C4, 90-E5, 90-E6, 90-F1 and 90-F2 according to the present invention have excellent attachment force with respect to a full-length spike protein of MERS-CoV and the S1 domain of the protein, and, of the monoclonal antibodies, the monoclonal antibodies 90-F1, 90-E5, 90-E6, 90-F2, 77-A5 and 77-A6 have excellent attachment force with respect to an RBD antigen of MERS-CoV. Also, the antibodies 77-A5, 77-A6, 90-E5, 90-E6, 90-F1 and 90-F2 exhibit neutralizing capacity with respect to a MERS pseudovirus and MERS-CoV, and the antibodies 90-B2 and 90-B7 exhibit neutralizing capacity only with respect to MERS-CoV. Further, the monoclonal antibodies have a particular monomeric form, and have excellent stability and thus may be useful for treating or diagnosing MERS.
Inventors:
LEE HANSAEM (KR)
CHOI JANGHOON (KR)
KIM SUNGSOON (KR)
WANG LINGSHU (US)
GRAHAM BARNEY (US)
MASCOLA JOHN (US)
CHOI JANGHOON (KR)
KIM SUNGSOON (KR)
WANG LINGSHU (US)
GRAHAM BARNEY (US)
MASCOLA JOHN (US)
Application Number:
PCT/KR2018/009754
Publication Date:
February 28, 2019
Filing Date:
August 23, 2018
Export Citation:
Assignee:
KOREA CENTER DISEASE CONTROL & PREVENTION (KR)
International Classes:
C07K16/10; A61K39/00; A61K47/68; G01N33/569
Foreign References:
| KR20170005133A | 2017-01-11 | |||
| KR20160055164A | 2016-05-17 |
Other References:
JIANG, L. ET AL.: "Potent Neutralization of MERS-CoV by Human Neutralizing Monoclonal Antibodies to the Viral Spike Glycoprotein", SCIENCE TRANSLATIONAL MEDICINE, vol. 6, no. 234, 30 April 2014 (2014-04-30), pages 1 - 10, XP009182042, DOI: doi:10.1126/scitranslmed.3008140
YING, T. ET AL.: "Exceptionally Potent Neutralization of Middle East Respiratory Syndrome Coronavirus by Human Monoclonal Antibodies", JOURNAL OF VIROLOGY, vol. 88, no. 14, July 2014 (2014-07-01), pages 7796 - 7805, XP009181617, DOI: doi:10.1128/JVI.00912-14
LEE, HANSAEM ET AL.: "Trend in Human Therapeutic MERS-CoV Antibody Development", PUBLIC HEALTH WEEKLY REPORT, vol. 9, no. 37, 8 September 2016 (2016-09-08), pages 727 - 732, XP055576995
YING, T. ET AL.: "Exceptionally Potent Neutralization of Middle East Respiratory Syndrome Coronavirus by Human Monoclonal Antibodies", JOURNAL OF VIROLOGY, vol. 88, no. 14, July 2014 (2014-07-01), pages 7796 - 7805, XP009181617, DOI: doi:10.1128/JVI.00912-14
LEE, HANSAEM ET AL.: "Trend in Human Therapeutic MERS-CoV Antibody Development", PUBLIC HEALTH WEEKLY REPORT, vol. 9, no. 37, 8 September 2016 (2016-09-08), pages 727 - 732, XP055576995
Attorney, Agent or Firm:
LEE, Won Hee (KR)
Download PDF: